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Abstract
AIM: To analyze the clinical and pathological parameters 
and expression of the neural cell adhesion molecule 
(CD56) in patients with biliary atresia (BA).
METHODS: Established clinical laboratory markers 
of hepatic function, including enzyme activity, protein 
synthesis, and bilirubin metabolism, were evaluated 
in patients with BA and compared with those in 
patients with choledochal cysts and neonatal hepatitis. 
Pathological changes in tissue morphology and fibrosis 
were examined by histological and tissue collagen 
staining. Immunohistochemical staining for the biliary 
epithelial cell markers CD56 and CK19 together with 
the Notch signaling related molecules Notch1 and 
Notch2 was performed in the context of alterations in 
the structure of intrahepatic biliary ducts.
RESULTS: Differences in some clinical laboratory 
Basic Study
ORIGINAL ARTICLE
parameters among the three diseases examined 
were observed, but they did not correlate with 
the pathological classification of fibrosis in BA. 
Immunohistochemical staining showed the presence 
of CD56-positive immature bile ducts in most patients 
(74.5%) with BA but not in patients with choledochal 
cysts or neonatal hepatitis. The number of CD56-
expressing cells correlated with disease severity, with 
more positive cells present in the later stages of liver 
damage (81.8% vs  18.2%).  Furthermore, bile plugs 
were mainly found in CD56-positive immature biliary 
ducts. Notch signaling was a key regulatory pathway 
in biliary duct formation and played a role in tissue 
fibrosis. Notch1 was co-expressed in CD56-positive 
cells, whereas Notch2 was found exclusively in blood 
vessels in the portal area of patients with BA. 
CONCLUSION: The maturation of biliary epithelial 
cells and the expression of Notch may play a role in the 
pathogenesis of BA.
Key words: Biliary atresia; CD56; Epithelial cell adhesion 
molecule; Cytokeratin 7; Biliary epithelial cells; Liver 
fibrosis
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Clinical laboratory parameters did not correlate 
with tissue fibrosis in patients with biliary atresia (BA). 
Immunohistochemical staining showed that CD56-
positive immature bile ducts were present only in 
patients with BA but not in those with choledochal cyst 
or neonatal hepatitis. The number of CD56 expressing 
cells correlated with disease severity, with more positive 
cells present in the later stages of liver damage. 
Furthermore, the signaling molecule Notch1, but not 
Notch2, was co-expressed in CD56 positive cells. Our 
data provide new insights into the pathogenesis of BA 
in terms of biliary epithelial cell maturation and Notch 
expression.
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INTRODUCTION
Biliary atresia (BA) is an infantile disorder that affects 
both intrahepatic and extrahepatic bile ducts, with 
progressive tissue fibrosis leading to irreversible liver 
cirrhosis[1]. With advances in clinical care and the 
availability of Kasai portoenterostomy to re-establish 
bile drainage, mortality has been significantly reduced; 
however, patients may still develop cirrhosis without 
liver transplantation[1,2]. The etiology of BA is still not 
fully understood, although a variety of pathological 
processes, such as viral infection[3], dysregulation of 
the immune system[4], and genetic defects, have been 
reported[5] in animal models and patients. It has also 
been proposed that the condition is multifactorial[6]. As 
transplantation is limited, advancing our knowledge on 
the pathological processes, such as inflammation and 
fibrosis, in BA may identify new therapeutic targets for 
treatment.
In patients with BA, an increase in bile ductules 
as the disease develops has been demonstrated, a 
process that is suggested to be associated with liver 
regeneration[7]. However, the function of these ductules 
is not fully understood, especially in liver fibrosis. 
Several markers have been used to differentiate 
biliary epithelial cells (BECs) from other hepatic cells 
and blood vessels. The most commonly used marker 
is cytokeratin 7 (CK7), which stains all BECs but also 
reacts with some progenitor hepatocytes[8]. Some 
investigators have used CD56 (neural cell adhesion 
molecule, NCAM) to identify immature BECs and 
epithelial cell adhesion molecule (EpCAM) as a marker 
of mature BECs, and antibodies specific for these 
molecules have been successfully used to isolate BECs 
from animal and human samples[9]. The expression of 
CD56 in patients with BA has been described in some 
studies[10,11], however, the function and relationship of 
this marker with the pathological changes that occur in 
BA have not been well studied. 
Notch signaling plays a key role in the development 
of the biliary system[12]. Alagille syndrome is caused 
by mutations in Jagged1, which encodes a ligand for 
Notch1, resulting in a loss of bile duct structure in the 
portal tracts[13]. However, Notch signaling contributes 
to the pathology of carbon tetrachloride-induced 
liver fibrosis in an animal model, and use of the 
inhibitor γ-secretase reduces fibrosis[14]. In addition, 
in Alagille syndrome, although cholestasis is severe, 
progression to biliary cirrhosis is rare[15], further 
indicating that Notch1-mediated signaling contributes 
to tissue fibrosis. Notch2 functions in normal peri- 
and post-natal formation of the intrahepatic bile 
duct (IHBD), and low expression of this receptor 
causes malformation of the IHBD. Notch2 can also 
influence the development of blood vessels[16]. As the 
pathological processes in BA include the formation of 
neo-ductules and tissue fibrosis, the function of Notch 
signaling in BA warrants investigation. 
In this study, we report differences in serum levels 
of markers of bile metabolism, i.e., total bilirubin (TBIL), 
direct bilirubin (DBIL), and total bile acid levels (TBA), 
in three cholestatic diseases: BA, neonatal hepatitis 
(NH), and choledochal cysts (CCs). Significantly 
higher levels of TBIL, DBIL, and TBA were found in 
patients with BA and NH compared to those with CC, 
which suggests that the liver, but not extra-hepatic 
structures, influences function. In addition, we noted 
that gamma-glutamyl transferase (γ-GT), which 
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reflects involvement of BECs, was increased in BA, but 
was less pronounced in NH. Detailed analysis of the 
phenotype of BECs in the context of CD56, EpCAM, and 
CK7 expression was performed in order to determine 
the different stages of maturation. Biliary epithelial 
cells stained for CD56 were present in higher numbers 
in patients with BA compared to those with CC or NH, 
which implies that neo-BECs might contribute directly 
to liver fibrosis. As Notch signaling is related to tissue 
fibrosis, increased expression of Notch1 in these cells 
suggests that CD56-related Notch signaling may also 
be involved in the pathogenesis of BA.
MATERIALS AND METHODS
Materials
The Trichrome Stain (Masson) Kit, Sirius Red, and 
other chemical reagents used were purchased from 
Sigma (Sigma-Aldrich Corporation, St Louis, MO, 
United States). Antibodies used were mouse anti-
human CD56 (Dako Denmark, Glostrup, Denmark), 
mouse anti-human EpCAM, and mouse anti-human 
CK7 (Santa Cruz Biotechnology, Dallas, TX, United 
States), rabbit anti-human Notch1 (Cell Signaling 
Technology, Beverly, MA, United States), and rabbit 
anti-human Notch2 (Bethyl Laboratories, Montgomery, 
TX, United States).
Patients’ medical histories
Patients’ medical histories were obtained from the 
patient record system of Guangzhou Women and 
Children’s Medical Center, China. Clinical information 
relevant to this study is shown in Table 1. The age of 
patients with BA and NH was often less than 1 year, 
whereas the age of patients with CC varied from 4 
months to 10 years, therefore, the latter group was 
further categorized by age (i.e., CC-AM < 1 year 
old) and then compared. The experimental protocols 
were approved by the Medical Ethics Committee of 
Guangzhou Women and Children’s Medical Center. 
Clinical laboratory investigations
To compare differences in the biochemical parameters 
for BA, CC, and NH, the serum levels of 10 biochemical 
parameters were measured and analyzed. The serum 
samples were obtained from patients before surgery 
and were analyzed using a Hitachi Pre-Analytical 
Process Automation System with a 7600 Clinical 
Analyzer. The 10 parameters analyzed were alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), γ-GT, total protein (TP), albumin (ALB), globulin 
(GLO), TBIL, DBIL, indirect bilirubin (IBIL), and TBA. 
Histology analysis and evaluation of tissue fibrosis 
Tissue fibrosis is one of the key pathophysiological 
changes in patients with BA and is often an indicator 
of an adverse clinical outcome. The deposition of 
tissue collagen was assessed as a clinical pathological 
parameter and classified according to the degree 
of tissue fibrosis by the pathology department. To 
confirm the clinical observations, sections were stained 
with Masson’s Trichrome Stain. In brief, the paraffin 
sections obtained from the pathology department 
were dewaxed and hydrated in xylene and descending 
concentrations of ethanol. The pathological changes 
were illustrated by Hematoxylin and Eosin staining. 
For Masson’s Trichrome staining, the sections were 
re-fixed in Bouin’s solution and then stained with 
Weigert’s iron hematoxylin solution before Biebrich 
scarlet-acid fuchsin solution was added. The color was 
differentiated in phosphomolybdic-phosphotungstic 
acid solution until the collagen was no longer red. The 
sections were then transferred to aniline blue solution 
and finally differentiated in 1% acetic acid solution. 
To confirm deposition of collagen, the adjacent 
sections were de-waxed and hydrated, and Sirius 
Red was applied for 1 h at room temperature; after 
counterstaining with hematoxylin, the sections were 
mounted and analyzed.
Immunohistochemical analysis
Tissue sections were dewaxed and hydrated as 
described above. Depending on the antibody, antigen 
retrieval was performed on the sections in 0.01 M 
citrate buffer (pH 6.0) for EpCAM, CK7, and Notch2, 
or tris-ethylenediaminetetraacetic acid (EDTA) buffer 
(pH 9.0) for CD56, Notch1, and CD31 in a microwave 
for 10 min at 95 ℃. Endogenous peroxidase was 
quenched with 3% hydrogen peroxide (H2O2) for 10 
min, and non-specific signals were blocked by the 
addition of 0.1% bovine serum albumin (BSA) and 
0.1% goat serum for 30 min at room temperature. The 
antibodies (1:50-1:200 in dilution buffer, Dako) were 
added and incubated at 37 ℃ for 60 min or overnight 
at 4 ℃. The signals were revealed by the Dako 
EnVision System (Dako Denmark, Glostrup, Denmark) 
with diaminobenzidine (DAB) or the Polink DS-MR-
Hu C1 kit for double staining following the manufac-
turer’s instructions. The sections were observed using 
Nikon Eclipse Ci (Nikon Instruments (Shanghai) Co., 
Ltd., Shanghai, China) and photographed with NIS-
Elements software (Nikon Instruments).
2547 February 28, 2016|Volume 22|Issue 8|WJG|www.wjgnet.com
Table 1  Patient medical histories
Patient 
characteristic
Disease
BA-E BA-ML NH CC CC-AM
Number 41 44 32 65 32
Age1 (mo) 2.2 ± 1.0 2.4 ± 1.7 1.9 ± 1.0 43.4 ± 31.6 2.9 ± 2.5
Sex M: 19
F: 22
M: 30
F: 14
M: 23 
F: 9
M: 17
F: 47
M: 9 
F: 23
1mean ± SD. BA: Biliary atresia; BA-E: Early stage of BA with less tissue 
fibrosis; BA-ML: Middle or late stage BA with more or dense tissue 
fibrosis; CC: Choledochal cyst; CC-AM: Patients aged < 1 year with CC; F: 
Female; M: Male.
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the means of ALT in BA, NH, and CC patients [F (2, 
180) = 5.702, P = 0.0040] and in BA, NH, and CC-
AM patients [F (2, 148) = 4.048, P = 0.0194]. There 
was no statistically significant difference when the 
patients with BA were compared to those with CC or 
NH, although there were differences between patients 
with NH and both the overall CC group and the CC-
AM subgroup (P < 0.01 and P < 0.05, respectively). 
There were differences in the means of γ-GT between 
BA, NH, and CC patients [F (2, 179) = 11.57, P < 
0.0001] and between BA, NH, and CC-AM [F (2, 148) 
= 9.927, P < 0.0001]. Markedly higher levels of γ-GT 
were observed in patients with BA (898.0 ± 724.0 
U/L), which were 3-fold higher than in the NH group 
(271.7 ± 297.6 U/L, P < 0.001) and 1.5-fold higher 
than in the CC group (575.4 ± 644.8 U/L, P < 0.05). 
There was no significant difference in γ-GT between BA 
and CC-AM groups, although the level in the CC-AM 
group was higher (786.9 ± 759.2 U/L). Furthermore, 
the high level of γ-GT in the CC-AM group reached 
significance compared with the NH group (P < 0.01).
Bilirubin metabolism is one of the most important 
indicators of liver function. Levels of all three bilirubin 
proteins (TBIL, DBIL, and IBIL) were higher than the 
upper limit of the normal ranges in the three diseases 
studied. In terms of TBIL, one way ANOVA showed 
differences in the means of these three proteins in BA, 
NH, and CC patients [F (2, 180) = 30.48, P < 0.0001], 
and in BA, NH and CC-AM patients [F (2, 148) = 6.469, 
P = 0.0020], when compared with the CC group (88.8 
± 100.8 μmol/L). The levels of TBIL were significantly 
higher in the BA and NH groups (184.8 ± 60.6 μmol/L 
and 199.0 ± 96.5 μmol/L, respectively; P < 0.001 for 
both) and the CC-AM group (130.7 ± 116.8 μmol/L, 
P < 0.01). Similarly, differences in the means of 
DBIL were observed in the three groups [CC; F (2, 
Statistical analysis
All clinical data are presented as mean ± standard 
deviation (SD). The statistical analysis was performed 
using GraphPad® Prism software (GraphPad Software, 
Inc., La Jolla, CA, United States). Student’s t test was 
used when comparing two sets of data and one way 
analysis of variance (ANOVA) was used when three 
sets or more were compared. The Tukey multiple 
comparison test was used for statistical analysis of 
each individual comparison within a group. P values < 
0.05 were considered statistically significant.
RESULTS
Differences in biochemical parameters in patients with 
BA, CC, and NH 
Overall, none of the parameters was significantly 
different when the CC-AM group was compared with 
CC group using the Student’s t test (Table 2). However, 
when CC-AM patients were compared with CC patients 
excluding the CC-AM group (i.e., CC-AM patients vs 
CC patients aged > 1 year), the level of γ-GT was 
significantly different (786.9 ± 759.2 U/L vs 357.2 ± 
408.4 U/L, respectively, P < 0.01), as was TBIL (130.7 
± 116.8 μmol/L vs 46.9 ± 58.2 μmol/L, respectively, P 
< 0.001). The difference in TBIL might have arisen due 
to increased levels of IBIL in the CC-AM patients (68.4 
± 88.1 μmol/L vs 14.9 ± 16.7 μmol/L, respectively, P 
< 0.01). 
No differences in TP, ALB, GLO, or the ratio of ALB 
to GLO were observed between the three diseases 
compared with the normal ranges of expression of 
these biochemical markers. AST levels were higher 
than normal (> 3-fold) in all three patient groups, but 
there was no significant difference. Using one way 
ANOVA with regard to ALT, there were differences in 
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Table 2  Clinical laboratory analysis of molecules in blood related to liver function
Population Average (SD) value
ALT 
(U/L)
AST 
(U/L)
γ-GT 
(U/L)
TP 
(g/L)
ALB 
(g/L)
GLO 
(g/L)
ALB 
GLO
TBIL 
(μmol/L)
DBIL 
(μmol/L)
IBIL 
(μmol/L)
TBA 
(μmol/L)
Normal ranges 9-50 5-60 10-60 65-85 40-55 20-40 1.2-2.4 2-17 0-7 2-13.7 0-15
BA (n = 85) 183.8 
(167.9)
284.8 
(279.8)
898.0 
(724.0)
57.7 
(6.7)
39.0 
(5.6)
21.4 
(28.8)
2.4 
(0.9)
184.8 
(60.6)
136.7 
(45.7)
48.1 
(20.7)
169.7 
(79.5)
NH (n = 32) 251.9 
(391.2)
372.7 
(425.9)
271.7d 
(297.6)
61.3 
(40.5)
38.1 
(6.2)
39.4 
(132.8)
(2.5 
(0.8)
199.0 
(96.5)
134.0 
(86.7)
64.7 
(39.2)
158.0 
(96.0)
CC
All (n = 65) 105.0b 
(115.3)
208.9 
(252.1)
575.4c 
(644.8)
62.1 
(9.3)
41.1 
(5.6)
24.3 
(27.1)
3.2 
(8.8)
88.8f 
(100.8)
47.2h 
(61.0)
41.6 
(68.4)
77.7j,l 
(124.1)
Aged < 1 yr 
(n = 32)
88.6a  
(104.3)
245.6 
(326.1)
786.9e 
(759.2)
57.9 
(7.7)
39.6 
(5.0)
18.3 
(4.4)
2.3 
(0.5)
130.7g 
(116.8)
62.3i 
(71.4)
68.4 
(88.1)
83.9k,m 
(91.1)
Aged > 1 yr 
(n = 33)
117.3 
(116.8)
260.9 
(264.2)
357.2 
(408.4)
66.2 
(9.2)
42.6 
(5.8)
30.4 
(37.4)
4.1 
(12.4)
46.9 
(58.2)
32.0 
(44.6)
14.9 
(16.7)
71.8 
(150.7)
For the statistical analysis, the differences in BA, NH, and CC (total) for each clinical parameter were studied, we first used one-way ANOVA to determine 
whether the F test was significant and if so, Tukey’s multiple comparisons test was used. A similar procedure was used to analyze age-matched CC. 
Details of the F test results are shown in the results section. bP < 0.01 and aP < 0.05 vs NH; cP < 0.05 and dP < 0.001 vs BA; eP < 0.01 vs NH; fP < 0.001 and gP 
< 0.01 vs BA and NH; hP < 0.001  and iP < 0.001 vs BA and NH; jP < 0.001 and kP < 0.001 vs BA; lP < 0.01 and mP < 0.01 vs NH. ALB: Albumin; ALT: Alanine 
aminotransferase; AST: Aspartate aminotransferase; BA: Biliary atresia; CC: Choledochal cyst; DBIL: Direct bilirubin; γ-GT: Gamma-glutamyl transferase; 
GLO: Globulin; IBIL: Indirect bilirubin; NH: Neonatal hepatitis; TBA: Total bile acid; TBIL: Total bilirubin; TP: Total protein.
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180) = 46.06, P < 0.0001] and CC-AM; F (2, 148) = 
17.92, P < 0.0001]. Increased levels of serum DBIL 
were observed in the BA and NH groups (136.7 ± 
45.7 μmol/L and 134.0 ± 86.7 μmol/L, respectively) 
compared with the CC (47.2 ± 61.0 μmol/L) and CC-
AM (62.3 ±7 1.4 μmol/L) subgroups (P < 0.001 for 
all comparisons). Total bile acid levels reflect liver 
function in terms of fatty acid metabolism, and the 
pattern of high levels detected in patients with BA and 
NH compared to those with CC was similar to that for 
bilirubin. The same phenomenon was observed for 
TBA in the three groups, BA, and NH with either CC or 
CC-AM, and the differences were significant [F (2, 172) 
= 14.79, P < 0.0001] and [F (2, 140) = 10.50, P < 
0.0001]. Increased levels of TBA were observed in the 
BA and NH groups (169.7 ± 79.5 μmol/L and 158.0 ± 
96.0 μmol/L, respectively) compared with the CC and 
CC-AM groups (71.8 ± 150.7 μmol/L, P < 0.001 and 
83.9 ± 91.1 μmol/L, P < 0.01, respectively).
Evaluation of liver tissue fibrosis
In order to determine whether clinical laboratory 
parameters had any relation to tissue fibrosis, the 
collagen content in tissue sections was examined with 
Masson’s Trichrome Stain. We observed that low levels 
of collagen were deposited in patients with early liver 
damage [early stage of biliary atresia (BA-E)], in which 
there was neither fibrosis nor mild portal fibrosis[17,18], 
and similar results were obtained for patients with NH 
and CC. However, collagen deposits were markedly 
increased in patients with moderate or late liver 
damage [middle or late stage of biliary atresia (BA-
ML)], who were reported to have a high degree of 
fibrosis[17,18] (Figure 1 left panel). These results were 
confirmed by Sirius Red staining, which allowed more 
accurate quantification (Figure 1, right panel). 
The levels of biochemical parameters, especially 
γ-GT, TBIL, and DBIL, were significantly different in 
the three different cholestatic diseases, and these 
were reanalyzed in the context of the degree of 
tissue fibrosis, using BA-E and BA-ML as the stages 
of disease progression. There were no statistically 
significant differences, although the trend in the BA-ML 
group suggested that there might be increases in all 
three parameters compared with the BA-E group.
Bile plugs in liver samples from patients with BA
No significant differences in serum levels of the 
biochemical parameters of bilirubin metabolism 
were found between the BA-E and BA-ML groups, 
which suggested either a reduction in the expression 
of bilirubin-related molecules or impairment of the 
transport of these products. Accumulation of bile 
plugs is a hallmark of BA, and it can often be found 
in bile ducts or ductules (Figure 2A, B, E, and F). In 
contrast, the presence of bile plugs was much less 
marked in patients with NH and CC (Figure 2C and G; 
D and H). However, when using BA-E and BA-ML as 
the different stages of BA, no difference was found in 
the accumulation of bile plugs, which was extensive in 
both stages, and their presence in liver tissue was not 
evenly distributed.
Analysis of intrahepatic bile ducts
Changes in morphology of the IHBDs were further 
examined using different markers for BECs. CK7 has 
long been used as a marker for BECs and showed 
positive staining in all tissue sections examined in 
patients with BA, NH, and CC as well as the disease 
control (portal vein cavernous transformation, PVCT) 
(Figure 3A, D, G and J). However, CK7 staining was 
slightly weaker in BA, which may have been related 
to its immature status. Compared to the control, the 
number of CK7-positive cells was greatly increased 
in patients with BA, but less so in those with NH. In 
patients with CC, the number of cells was similar to 
that in the control. 
EpCAM is a marker of mature BECs and was 
expressed in BA, NH, CC, and the disease control 
(Figure 3B, E, H and K). The pattern of EpCAM staining 
was similar to that of CK7, but the number of cells was 
less pronounced than that detected for CK7. In some 
tissue sections, bile ducts in the portal tract did not 
stain with EpCAM; and, therefore, the staining pattern 
was different from that of CK7 (Figure 3M and N). 
CD56 is a marker of immature BECs. Marked 
expression of CD56-positive BECs was observed in 
patients with BA (Figure 3C), but not in those with 
NH, CC, or in normal control liver (Figure 3F, I and L). 
Using adjacent tissue sections from patients with BA, a 
partial co-localization of CD56 and CK7 was observed 
(Figure 3M and O).
Distribution of CD56-positive cells in patients with BA
Using adjacent tissue sections, expression of CD56 was 
further analyzed and was observed to co-localize with 
EpCAM (Figure 4A-H). The CD56-positive immature 
bile ducts were mostly found in the periportal tract, 
where bile plugs were often observed (Figure 4I). 
Inflammatory cell infiltration is an important event 
in the development of BA, and expression of major 
histocompatibility complex class Ⅱ [human leucocyte 
antigen (HLA)-DR] proteins was detected in tissue 
sections. The co-localization of CD56 and HLA-DR 
staining indicated the close relationship between these 
two sets of cells, and, in some instances, HLA-DR-
positive cells were found in CD56-positive immature 
bile ducts (Figure 4J).
Three categories of CD56 expression were identified 
based on the intensity of staining: strong (++) (Figure 4A 
and B), weak (+) (Figure 4C), and no signal (-) (Figure 
4D). In order to further understand the relationship 
between CD56, bile plugs and the pathological classi-
fication of BA-E and BA-ML, the percentage of each 
category was calculated for patients with BA (Table 3). 
Overall, the percentage of CD56++ was higher for BA-
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ML than for BA-E (57.1% vs 40.1%) and for sections 
with bile plugs than those without (51.2% vs 41.7%). 
Further analysis of the disease subcategories found that 
BA-E without bile plugs had a higher percentage of CD56- 
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Figure 1  Evaluation of tissue fibrosis in biliary atresia, choledochal cyst, and neonatal hepatitis patients. Liver tissues from patients with BA, CC, and NH 
were collected and adjacent sections were cut. Tissue fibrosis was evaluated with Masson’s Trichrome Stain, in which the collagen was detected by blue color. 
Depending on the stage of fibrosis, sections from patients with BA were further separated into two groups: early stage BA (BA-E), with no or mild collagen deposition, 
and middle or late stage BA (BA-ML), with dense collagen deposition. The adjacent tissue sections were further stained with Sirius Red to validate the results, with 
collagen detected by pink color. Sections were examined with a Nikon light microscope. Scale bar shown represents 50 μm. NH: Neonatal hepatitis; CC: Choledochal 
cyst; BA: Biliary atresia.
FB
EA
HD
GC
Masson’s Sirius red
BA
-E
BA
-M
N
H
CC
Zhang RZ et al . CD56+ epithelial cells in biliary atresia
cells than CD56+ cells (50% vs 16.7%) and BA-ML with 
bile plugs had a higher percentage of CD56+ than CD56- 
cells (54.4% vs 18.2%). These data suggest a positive 
correlation between CD56+ cells and disease progression.
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Figure 2  Comparison of bile plugs in biliary atresia, choledochal cyst, and neonatal hepatitis patients. HE staining was performed on tissue sections from 
patients with three cholestatic diseases: biliary atresia [early (BA-E) and middle and late (BA-ML)], CC, and NH. The sections were separated based on their serum 
levels of DBIL into two groups: bilirubin high (DBIL-H) and bilirubin low (DBIL-L), with the sections containing the highest number of bile plugs in each group selected 
and photographed. The sections were examined with a Nikon light microscope. Scale bar represents 50 μm. CC: Choledochal cyst; DBIL: Direct bilirubin; HE: 
Hematoxylin and eosin; NH: Neonatal hepatitis
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Figure 3  Immunohistochemical analysis of the expression of cytokeratin 7, epithelial cell adhesion molecule, and CD56. Tissue sections from patients 
with BA (A-C), NH (D-F), CC (G-I), and the disease control (J-L) together with a set of adjacent sections (M-O) were selected. Immunohistochemical staining was 
performed with antibodies for CK7 (A, D, G, J and M), EpCAM (B, E, H, K and N) and CD56 (C, F, I, L and O). After antigen retrieval, the sections were incubated with 
antibodies overnight at 37  ℃. The black arrow in (H) indicates a bile duct. The sections were examined with a Nikon light microscope. Scale bar represents 50 μm. 
EpCAM: Epithelial cell adhesion molecule; CK7: Cytokeratin 7; NH: Neonatal hepatitis; CC: Choledochal cyst; BA: Biliary atresia.
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Figure 4  Co-localization of CD56 with epithelial cell adhesion molecule, bile plugs, and human leucocyte antigen-DR. Co-localization of CD56 (A-D) and 
EpCAM (E-H) is illustrated in adjacent sections using immunohistochemical staining. From the upper (A, E) to the lower (D, H) slides, the full spectrum of the CD56 
staining results is shown. Co-localization of CD56 with bile plugs is shown in (I). Localization of CD56 and HLA-DR positive cells is shown in (J). Black arrows indicate 
bile plugs. Pink arrows indicate HLA-DR-positive cells. Dark green represents CD56-positive cells. The sections were examined and the scale bar represents 50 μm. 
Hep: Hepatocytes; PT: Portal tract; EpCAM: Epithelial cell adhesion molecule; HLA-DR: Human leucocyte antigen-DR.
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Expression of Notch signaling components in patients 
with BA
Notch signaling is involved in development of the bile 
duct system and also plays a role in tissue fibrosis. In 
order to study the relationship between CD56-positive 
BECs and the Notch signaling pathway, expression of 
the receptors Notch1 and Notch2 was investigated 
in patients with BA using immunohistochemistry and 
double staining. In age-matched liver tissue controls, 
Notch1 expression was detected in mature bile ducts 
in the portal area (Figure 5A). Expression of CD56 
was rarely detected in normal liver tissue, but, when 
observed, it was not co-localized with Notch1. In 
contrast, increased expression of CD56 was found in 
immature bile ducts in patients with BA, and most of 
them also expressed Notch1 (Figure 5B). Expression 
of Notch1 was detected mainly in the lumen of the bile 
ducts in both normal tissue and tissue from patients 
with BA, which suggests the presence of the secreted 
form of the protein. Expression of Notch2 was mainly 
in the blood vessels, both the hepatic arteries and 
portal veins, which are situated inside the portal area 
in healthy subjects and those with BA (Figure 5C-F). 
No co-localization of CD56+ and Notch2+ cells was 
observed in the portal tract (Figure 5D). However, 
increased CD31, one of the endothelial cell markers, 
was found in tissue from patients with BA, and co-
localization with Notch2 was observed. It is suggested 
that Notch signaling is increased in patients with BA, 
which may impact progression of tissue fibrosis.
DISCUSSION
In this study, we compared 10 clinical laboratory 
parameters in three neonatal cholestatic diseases 
and found similarities in most of the parameters 
examined. The levels of TP, ALB, and GLO, which 
reflect biosynthesis and storage of liver proteins, were 
similar to normal reference levels. Although there was 
variation between individual patients, it seems unlikely 
that these parameters are primarily responsible for 
severe liver damage. This is understandable, as 
blockade of bile transport in these three diseases is 
initially affected, while damage to the hepatocytes 
occurs only at the end stage of these conditions. 
Metabolism of bilirubin was the main feature that 
differentiated CC (including age-matched CC) from BA 
and NH, with the levels of DBIL being much lower in 
the CC group. This difference can be explained by the 
fact that CC mostly affects the extra-hepatic biliary 
ducts, but also damages the hepatocytes themselves 
and leakage of bile into the bloodstream is not severe. 
Similar results were obtained for TBIL and TBA, 
which indicates that metabolism of bilirubin was more 
severely impaired in patients with BA and NH than in 
those with CC. In terms of distinguishing BA and NH 
based on clinical laboratory parameters, only γ-GT 
showed different levels. In patients with NH, a 4-fold 
increase in γ-GT was observed compared to the upper 
limit of the normal range; however, γ-GT expression 
was increased 14-fold in patients with BA. Histological 
and immunohistochemical analyses showed more bile 
ducts and ductules in patients with BA than in those 
with NH. As γ-GT was expressed in both hepatocytes 
and BECs[19], higher numbers of BECs may be the 
source of increased levels of γ-GT. Our data validate an 
earlier report in which γ-GT was demonstrated to be 
a valuable indicator for distinguishing BA from NH[20]. 
However, as NH is a complex multi-factorial disease 
with variations in pathology, it is likely that some 
patients may develop BA in the later phase of the 
disease, and, therefore, the use of γ-GT as an exclusive 
clinical indicator requires caution. 
The transition from inflammation to fibrosis is 
a pathological change that occurs in patients with 
BA, although the time frame for this has not been 
conclusively defined[2]. Infiltration of inflammatory 
cells, proliferation of neovascular and neo-biliary 
epithelial cells, and accumulation of bile play a role 
in this process, which complicates the understanding 
of the pathophysiology of the disease. In an attempt 
to simplify the analysis of the disease processes, we 
separated liver damage into two stages - BA-E and 
BA-ML - with tissue fibrosis as the main discriminator. 
We found that there was no difference in the number 
of bile plugs in early fibrosis compared to late stage 
fibrosis. 
The number of bile plugs noted in bile ducts, which 
were occasionally found in hepatocytes, prompted 
us to study the morphology of the bile ducts. Using 
three different markers of BECs, we detected the 
presence of both CD56- and EpCAM-positive cells, 
which respectively reflect immature and mature BECs, 
and these two cell populations were a part of the 
cell population that stained with CK7. These results 
indicate that pathological changes develop in the biliary 
system of patients with BA. The expression of CD56 
in bile ductules discriminated between BA and both 
NH and CC, confirming previous observations[10,11,21]. 
We failed to detect CD56-positive cells in some tissue 
sections from patients with BA, but the presence of 
the mature BEC markers may indicate heterogeneity 
of the maturation process. Whether this reflects the 
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Table 3  Expression of CD56 in biliary atresia  n  (%)
Stage of BA n CD56++ CD56+ CD56-
All 55 27 (49.1) 14 (25.5) 14 (25.5)
   BA-E without bile plugs   6   1 (16.7)   2 (33.3)   3 (50.0)
   BA-E with bile plugs 21 10 (47.6)   5 (23.8)   6 (28.6)
   BA-ML without bile plugs   6   4 (66.7)   1 (16.7)   1 (16.7)
   BA-ML with bile plugs 22 12 (54.5)   6 (27.3)   4 (18.2)
All BA-E 27 11 (40.7)   7 (25.9)   9 (33.3) 
All BA-ML 28 16 (57.1)   7 (25.0)   5 (17.9)
All without bile plugs 12   5 (41.7)   3 (25.0)   4 (33.3)
All with bile plugs 43 22 (51.2) 11 (25.6) 10 (23.3)
BA: Biliary atresia; BA-E: Early stage of BA with less tissue fibrosis; BA-
ML: Middle or late stage BA with more extensive or dense tissue fibrosis.
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early phase of “ductal reaction” warrants further 
study. Nevertheless, even in the absence of CD56-
positive cells, the possibility of BA cannot be excluded. 
Our observation that progression of BEC maturation 
reduced the expression of CD56 also suggests that 
analyzing the expression of EpCAM might help to 
clarify further events in the development of BA. As CK7 
also stains ductal hepatocytes, or oval cells[22], which 
are progenitors of BECs, it may aid in understanding 
the origin of CD56-positive cells. The combined use 
of these three markers for BECs will extend our 
understanding of the function of BECs in the BA 
disease process.
Liver tissue regeneration offers some compensation 
for lost organ function arising from these diseases, 
and it has been suggested that the presence of CD56 
positivity is a sign of tissue repair[21]. However, in 
this study, we found that newly formed bile ductules 
often co-localized with bile plugs. Analysis of the 
morphology of the ductules with CD56-positive 
staining often showed no lumen, and as maturation 
progressed, we noted that the CD56 signal reduced, 
but increased for EpCAM, which resulted in an increase 
in the lumen area. However, the high expression of 
CD56 in BA suggests that there is inhibition of the 
maturation process. Furthermore, bile accumulation 
contributes to liver fibrosis, as demonstrated by the 
finding that ligation of the bile duct can directly induce 
liver fibrosis[23]. The presence of CD56 implies the 
progression of BA to liver fibrosis. This, together with 
evidence for Notch signaling in CD56-positive cells, 
further increases the possibility of liver fibrosis, as this 
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Figure 5  Expression of Notch signaling components in biliary atresia. Co-localization of CD56-positive cells with Notch1 (A and B) and Notch2 (C and D) is 
illustrated by immunohistochemical double staining with mouse anti-human CD56 and rabbit anti-human Notch1 and Notch2 using the Polink DS-MR-Hu C1 kit. 
Positive signals are indicated by arrows, with corresponding colors in the side bars. Scale bar represents 50 μm. BD: Bile duct; HA: Hepatic artery; PV: Portal vein.
Control
C
BA
D
BA
CD
56
-N
ot
ch
1
CD
56
-N
ot
ch
2
CD
31
-N
ot
ch
2
FE
HA
PV
HA
PV
PV
PV
HA
HA
BD
BD
Zhang RZ et al . CD56+ epithelial cells in biliary atresia
signaling pathway plays a key role in the development 
of fibrosis directly within tissues[24] and by the 
infiltration of inflammatory cells[25]. Our data suggest 
that the presence of CD56-positive BECs might 
promote deleterious outcomes in the progression of 
BA. We also demonstrated that CD56-positive cells are 
often surrounded by HLA-DR expressing cells, which 
is in agreement with previous studies[26,27]. Therefore, 
it is possible that CD56-positive BECs from ductal 
hepatocytes may interact with the inflammatory cell 
infiltrate. Our results are compatible with extrahepatic 
bile duct blockade and inflammatory cellular infiltration 
acting together to promote the pathogenesis of 
BA. The presence of CD56-positive cells does not 
ameliorate the pathological condition but, in contrast, 
accelerates the development of tissue fibrosis. 
In conclusion, our study shows that levels of 
bilirubin-related parameters, such as TBIL, DBIL, 
and TBA, are higher in patients with BA and NH and 
moderately high in patients with CC. Furthermore, 
γ-GT was significantly increased in patients with BA 
as compared to those with NH. This change might 
be related to the increased levels of CD56-positive 
immature BECs in patients with BA. However, newly 
formed immature bile ducts or ductules have no bile 
transport function and bile may accumulate to form 
bile plugs. Enhanced expression of Notch signaling in 
CD56-positive cells further increases the possibility 
of progression to liver cirrhosis. Inhibition of the 
formation of CD56-positive BECs or the promotion 
of maturation of these cells may help to reduce BA 
progression to cirrhosis. 
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